From: Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial
Variable | Â | Â |
---|---|---|
Age, n (%) | Â | Â |
   <65 | 40 | (80) |
   65 or more | 10 | (20) |
Histotype, n (%) | Â | Â |
   Ductal | 41 | (82) |
   Lobular | 6 | (12) |
   Other | 3 | (6) |
ER status, n (%) | Â | Â |
   Negative | 19 | (38) |
   Positive | 30 | (60) |
   Unknown | 1 | (2) |
Performance status, n (%) | Â | Â |
   0 | 41 | (82) |
   1 | 7 | (14) |
   2 | 2 | (4) |
HER2 status, n (%) | Â | Â |
   Score 3+ by IHC | 47 | (94) |
   Score 2+ and positive by FISH | 3 | (6) |
Time from breast cancer diagnosis, n (%) | Â | Â |
   <2 years | 19 | (38) |
   2 years or more | 31 | (62) |
Previous chemotherapy, n (%) | Â | Â |
   No | 9 | (18) |
   Yes | 41 | (82) |
By type of drugs | Â | Â |
CMF | 4 | (8) |
with anthracycline | 24 | (48) |
with anthracycline and taxane | 13 | (26) |
By number of lines of chemotherapy | Â | Â |
one line | 26 | (52) |
two lines | 15 | (30) |
Extension of disease, n (%) | Â | Â |
   By number of involved organs |  |  |
1 | 27 | (54) |
2 | 16 | (32) |
3 | 7 | (14) |
   By dominant metastatic site |  |  |
soft tissues | 13 | (26) |
viscera | 37 | (74) |
Eligible for response assessment, n (%) | Â | Â |
   No | 10 | (20) |
   Yes | 40 | (80) |